OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Mirza on the FDA Approval of Dostarlimab Plus Chemotherapy in dMMR/MSI-H Endometrial Cancer

July 31st 2023

Mansoor Raza Mirza, MD, discusses the significance of the FDA approval of dostarlimab in combination with chemotherapy in patients with mismatch repair–deficient or microsatellite instability–high endometrial cancer.

Dr Hitchcock on Potential Clinical Implications of the ERAsur Trial in Limited mCRC

July 31st 2023

Kathryn Hitchcock, MD, PhD, expands on potential clinical implications of the ongoing phase 3 ERAsur trial in metastatic colorectal cancer

Dr Wise on Key Trials Establishing Treatment Intensification as a SOC in mHSPC

July 31st 2023

David R. Wise, MD, PhD, discusses key trials establishing the benefit of hormone therapy– or chemotherapy-based doublet therapy for patients with metastatic hormone-sensitive prostate cancer

Dr Moore on Investigating Ubamatamab Plus Cemiplimab in Recurrent Ovarian Cancer

July 29th 2023

Kathleen N. Moore, MD, MS, discusses the investigation of ubamatamab alone or in combination with cemiplimab in patients with recurrent ovarian cancer.

Dr Buchbinder on Treatment Decisions After Severe irAEs With Nivolumab/Ipilimumab in Melanoma

July 29th 2023

Elizabeth Buchbinder, MD, discusses the rationale for investigating nivolumab maintenance therapy in patients with melanoma who experienced severe immune-related adverse effects due to combination therapy with nivolumab and ipilimumab, and details the findings of this investigation.

Dr Tsuboi on Updated Survival Results of the ADAURA Trial in Resectable NSCLC

July 29th 2023

Masahiro Tsuboi, MD, discusses the updated survival results of the phase 3 ADAURA trial in resectable EGFR-mutant non–small cell lung cancer.

Dr Bazhenova on Potential Combination Strategies With KRAS G12C Inhibitors in Advanced NSCLC

July 29th 2023

Lyudmila A. Bazhenova, MD, discusses potential combination strategies with KRAS G12C inhibitors in advanced non–small cell lung cancer.

Dr Santos on Testing and Treatment in NRG1 Fusion–Positive NSCLC

July 29th 2023

Edgardo Santos, MD, FACP, FCCP, discusses testing and treatment in NRG1 fusion–positive non–small cell lung cancer.

Dr Mohty on Bispecific Antibodies in R/R Multiple Myeloma

July 28th 2023

Mohamad Mohty, MD, PhD, discusses unmet needs in patients with relapsed/refractory multiple myeloma and the rationale for investigating elranatamab monotherapy in this population in the phase 2 MagnetisMM-3 trial.

Dr Shah on the Background of the BRUIN Trial in Relapsed/Refractory MCL

July 28th 2023

Nirav N. Shah, MD, discusses the background of the phase 1/2 BRUIN trial of pirtobrutinib in patients with heavily pretreated, relapsed/refractory mantle cell lymphoma.

Dr Bewersdorf on Ruxolitinib Plus Abemaciclib in Myelofibrosis

July 28th 2023

Jan Bewersdorf, MD, discusses the design of an ongoing phase 1 trial investigating ruxolitinib plus abemaciclib in patients with primary or secondary myelofibrosis.

Dr Growdon on the Withdrawal of Later-Line Indication For Olaparib in BRCA-Mutated Ovarian Cancer

July 28th 2023

Whitfield B. Growdon, MD, expands on the FDA’s decision to withdraw the later-line indication of olaparib for patients with BRCA-mutated ovarian cancer.

Dr Waks on Later-Line Treatment Options in HER2+ Breast Cancer

July 28th 2023

Adrienne G. Waks, MD, discusses treatment alternatives in the third line and beyond for patients with metastatic HER2-positive breast cancer.

Dr Peters on Understanding Mechanisms of Resistance to Immunotherapy in NSCLC

July 27th 2023

Solange Peters, MD, PhD, discusses current understandings of mechanisms of resistance to immunotherapy in non–small cell lung cancer.

Dr Kim on Improving Representation in Clinical Trials

July 27th 2023

Edward S. Kim, MD, MBA, discusses the importance of improving representation in clinical trials.

Dr Tarantino on the Impact of Emerging ADCs in HR+ Breast Cancer

July 27th 2023

Paolo Tarantino, MD, discusses the evolution and impact of the continued investigation of antibody-drug conjugates in the treatment of patients with hormone receptor–positive breast cancer.

Dr Bal on Sequencing Considerations for BMCA- and GPRC5D-Targeted Agents in Multiple Myeloma

July 27th 2023

Susan Bal, MD, discusses questions remaining regarding sequencing of treatments in later lines for patients with relapsed/refractory multiple myeloma.

Dr Wander on Using Platinum Chemotherapy Wisely in Breast Cancer

July 27th 2023

Seth Wander, MD, PhD, discusses challenges related to the ongoing platinum chemotherapy shortage for patients with breast cancer and other malignancies, as well as ways that oncologists and cancer centers can operate during the shortage to continue to provide appropriate care for patients.

Dr Roof on Disparities in Lung Cancer Mortality Rates in the United States

July 27th 2023

Logan Roof, MD, discusses findings from a study investigating trends in lung cancer mortality across different sociodemographic populations and locations in the United States between 1999 and 2020.

Dr Weiss on the Ongoing Investigation of Tebentafusp With or Without Pembrolizumab in Non-Uveal Melanoma

July 27th 2023

Sarah Weiss, MD, discusses the ongoing phase 2/3 TEBE-AM trial of tebentafusp with or without pembrolizumab in a subset of pretreated patients with non-uveal melanoma.